US Patent
US10398791 — Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
Composition of Matter · Assigned to Deutsches Krebsforschungszentrum DKFZ · Expires 2034-10-17 · 8y remaining
Vulnerability score
12/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects compounds represented by Formulae (Ia) or (Ib) for use as radiopharmaceuticals in the treatment of prostate cancer.
USPTO Abstract
The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.